ClinicalTrials.gg

Program

anrikefon

Also written as “HSK21542”, “HSK21542 Injection” and “HSK21542 dose level 1”.

Its studies are mostly in Pruritus · Pain, Postoperative · Renal Insufficiency, led by Haisco Pharmaceutical Group.

Furthest: phase 3, since Jan 31, 202115 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Haisco Pharmaceutical Group152 open or runningphase 3since Jan 31, 2021Aug 27, 2019none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 27, 2019First study: phase 1 study in Pain, PostoperativeFirst studyNCT04110886 · 120 enrolled · Australia
  2. Dec 25, 2019Phase 1 study in Healthy VolunteersNCT04213196 · 66 enrolled · China
  3. Jun 3, 2020Phase 2 study in AgnosiaNCT04424251 · 124 enrolled · China
  4. Jul 7, 20202 phase 2 studiesNCT04470154, NCT04470128
  5. Jan 31, 2021Phase 3 study in Postoperative AnalgesiaNCT04738357 · 276 enrolled · China
  6. Aug 4, 2021Phase 2 study in PruritusNCT04999787 · 90 enrolled · China
  7. Nov 15, 2021Phase 3 study in PruritusNCT05135390 · 545 enrolled · China
  8. May 12, 2022Phase 3 study in Postoperative AnalgesiaNCT05390905 · 387 enrolled · China
  9. Apr 19, 2023Phase 1 study in Peripheral Analgesic and Anti-itchNCT05835934 · 6 enrolled · China
  10. Jun 29, 2023Phase 1 study in Renal InsufficiencyNCT05947097 · 32 planned · China
  11. Jan 21, 2024Phase 1 study in Chronic Kidney Disease PatientsNCT06238388 · 6 enrolled · China
  12. Feb 7, 2024Phase 2 study in PruritusNCT06290375 · 250 planned
  13. Sep 4, 2025Phase 3 study in Postoperative Pain ManagementNCT07186426 · 405 enrolled · China
  14. Feb 11, 2026Phase 2 study in Postoperative Pain ManagementNCT07442877 · 161 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07442877Postoperative Pain Management · China2CompletedJan 24, 2025161
NCT07186426Postoperative Pain Management · China3CompletedFeb 24, 2026405
NCT06290375Pruritus2Not yet recruitingMar 8, 2024250
NCT06238388Chronic Kidney Disease Patients · China1CompletedNov 21, 20236
NCT05947097Renal Insufficiency · China1RecruitingJul 30, 202332
NCT05835934Peripheral Analgesic and Anti-itch · China1CompletedSep 10, 20216
NCT05390905Postoperative Analgesia · China3CompletedDec 16, 2022387
NCT05135390Pruritus · China3CompletedJul 27, 2023545
NCT04999787Pruritus · China2CompletedAug 3, 202290
NCT04738357Postoperative Analgesia · China3CompletedJul 30, 2021276
NCT04470154Uremic Pruritus · China2CompletedOct 28, 2021131
NCT04470128Agnosia · China2CompletedDec 28, 2020180
NCT04424251Agnosia · China2CompletedDec 7, 2020124
NCT04213196Healthy Volunteers · China1CompletedSep 6, 202066
NCT04110886Pain, Postoperative · Australia1CompletedDec 8, 2020120

How it is read

Names in the registry

  • “HSK21542”, 14 entries
  • “HSK21542 Injection”, 3 entries
  • “HSK21542 dose level 1”, 1 entry
  • “HSK21542 dose level 2”, 1 entry
  • “Experimental: stage I:HSK21542 0.4 μg/kg”, 1 entry

Codes read as this program: HSK21542.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
anrikefon (Haisco Pharmaceutical Group): development program | ClinicalTrials.gg